Click‐Chemistry Functionalized Lipid Nanoparticles for In Vitro and In Vivo Transfection of Primary Human CD4 + T Cells
Advanced Healthcare Materials · 2026
DOI: 10.1002/adhm.71747 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2026. Verfasst von Maaike De Cock und 5 weiteren Autor:innen. Beteiligte Einrichtung: HIV Cure Research Center, Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Belgium. Hauptthemen laut MEDLINE: Nanoparticles, CD4-Positive T-Lymphocytes, Transfection, Lipids. Die Arbeit nennt 53 Literaturangaben. Gefördert von: Research Foundation Flanders, Ghent University Special Research Fund (BOF), Fonds Wetenschappelijk Onderzoek.
Abstract (Originalsprache)
CD4 + T cells orchestrate adaptive immunity and strategies that enable their genetic reprogramming hold promise for treating cancer, immune dysregulation and infectious diseases such as HIV. However, current T cell engineering approaches rely heavily on ex vivo manipulation, which is labor‐intensive, costly, and can alter cell phenotypes. Lipid nanoparticles (LNPs) offer a scalable nonviral alternative, yet conventional formulations show minimal interaction with lymphocytes and are rapidly cleared by the liver. In this study, we develop a modular DBCO‐azide click‐chemistry approach to functionalize LNPs with a high‐affinity CD4 nanobody, enabling precise CD4 receptor‐directed delivery to human CD4 + T cells. Optimized CD4‐targeted LNPs transfect up to 48% of non‐activated CD4 + T cells within a PBMC co‐culture, the highest efficiency reported so far through LNP transfection. Moreover, they successfully deliver CRISPR‐Cas9 components to activated CD4 + T cells and achieve up to 32% gene editing. In humanized NSG‐SGM3 mice, CD4‐targeted LNPs selectively associate with and transfect circulating and bone marrow–resident human CD4 + T cells while showing minimal off‐target activity in murine cells. These results establish CD4‐nanobody LNPs as a versatile platform for targeted mRNA and gene‐editing delivery, with broad potential for cancer immunotherapy, T cell reprogramming, and HIV cure strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HIV Cure Research Center, Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Belgium.
- Biopharmaceutical Technology Unit, Department of Pharmaceutics, Faculty of Pharmaceutics, Ghent University, Belgium.
- Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, Ghent University, Belgium.
- Laboratory of Virology, Department of Translational Physiology, Infectiology, and Public Health, Faculty of Veterinary Medicine, Ghent University, Belgium.
ORCID-Profile: Maaike De Cock
Förderung
- Research Foundation Flanders
- Ghent University Special Research Fund (BOF)
- Fonds Wetenschappelijk Onderzoek
Zitieren
APA
De Cock, M., Burg, E., Gerlo, S., Vandekerckhove, L., De Geest, B. G., & Van Cleemput, J. (2026). Click‐Chemistry Functionalized Lipid Nanoparticles for In Vitro and In Vivo Transfection of Primary Human CD4 + T Cells. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71747
Vancouver
De Cock M, Burg E, Gerlo S, Vandekerckhove L, De Geest BG, Van Cleemput J. Click‐Chemistry Functionalized Lipid Nanoparticles for In Vitro and In Vivo Transfection of Primary Human CD4 + T Cells. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71747
BibTeX
@article{DeCock2026,
author = {De Cock, Maaike and Burg, Elianne and Gerlo, Sarah and Vandekerckhove, Linos and De Geest, Bruno G and Van Cleemput, Jolien},
title = {Click‐Chemistry Functionalized Lipid Nanoparticles for In Vitro and In Vivo Transfection of Primary Human CD4 + T Cells},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71747}
}
EUVIMED